Immune globulin 16.5% - Octapharma

Drug Profile

Immune globulin 16.5% - Octapharma

Alternative Names: Gammanorm; Octanorm

Latest Information Update: 28 Jul 2016

Price : $50

At a glance

  • Originator Octapharma
  • Developer Aarhus Universitetshospital; Octapharma; Rigshospitalet
  • Class Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Immunodeficiency disorders
  • Clinical Phase Unknown Chronic inflammatory demyelinating polyradiculoneuropathy; Motor neuron disease

Most Recent Events

  • 01 Jul 2016 Octapharma plans the observational Immunorm clinical trial for Autoimmune disorders in France (SC) (ISRCTN32265704)
  • 15 Mar 2016 Biomarkers information updated
  • 14 Dec 2015 Octapharma plans a phase III trial in Immunodeficiency disorders patients who have completed the SCGAM-01 trial in USA (NCT02627300)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top